Baş boyun kanserli hastalarda tedavi sonuçları ve prognostik faktörler

Volume: 35 Number: 1 March 22, 2013
EN TR

Baş boyun kanserli hastalarda tedavi sonuçları ve prognostik faktörler

Öz

Özet

Amaç. Merkezimizde takip ve tedavi edilen baş boyun kanseri hastalarında klinikopatolojik özelliklerin, tedavi sonuçlarının ve sağkalımı etkileyen prognostik faktörlerin incelenmesi amaçlanmıştır. Yöntem. 2007-2010 tarihleri arasında merkezimize başvuran ve baş boyun kanseri tanısı ile izlenmekte olan hastalara ait demografik, klinik ve histopatolojik veriler hasta dosya ve hastane kayıtları incelenerek elde edildi. Bulgular. Seksen iki hastaya ait veriler analiz edildi. 72 erkek (%88) ve 10 kadın (%12) hasta mevcuttu. Hastaların ortanca yaşı 57 (20-80) idi. En genç hastalar nazofarenks, parahipofarenks ve paranazal sinüs tümörü olan hastalardı. En yaygın malignensi 37 hastada (%45) bulunan larenks kanseri idi. Elli beş hasta (%67) Eastern Cooperative Oncology Group 1 idi. En sık evre 51 hasta (%62) ile lokal ileri evre idi. Tanı anında 60 (%75) hastada anemi, 30 (%60) hastada C- reaktif protein yüksekliği, 72 (%89) hastada kilo kaybı tespit edildi. Yassı hücreli karsinom 69 (%84) hasta  ile en sık izlenen histopatolojik tip idi. On yedi (%47) hastada perinöral invazyon, 17 (%47) hastada lenfovasküler invazyon, 12 (%32) hastada ekstrakapsüler invazyon tespit edildi. Hastalar arasında en sık izlenen grade 34 (%42) hasta ile grade II idi. Tüm hastalar için ortanca sağkalım 34 aydı. İki yıllık genel sağkalım oranı erken evre (I-II) hastalarda %75, lokal ileri hastalarda (III-IVA ve B) %51 iken, metastatik hastalık varlığında ise ortanca sağkalım 10 ay idi. Eşlik eden hipertansiyon varlığı, performans durumu, kanserin lokalizasyonu ve evresi, T ve N evresi, radyoterapiye ara verilmesi, C- reaktif protein düzeyi ve anemi sağkalımı belirleyen faktörler idi. Sonuç. Hipertansiyon varlığı, performans durumu, kanserin lokalizasyon ve evresi, T ve N evresi, radyoterapiye ara verilmesi, C- reaktif protein düzeyi ve anemi baş boyun kanserli hastalarda sağkalımı etkileyen prognostik faktörler olarak belirlendi.

Anahtar sözcükler: Baş boyun kanseri, radyoterapi, kemoterapi, prognoz

 

Abstract

Aim. Our aim was to investigate the clinicopathological features, the treatment outcome and the prognostic factors affecting survival in patients with head and neck cancer followed and treated in our center. Methods. The demographic, clinical and the histopathological data of the patients who were admitted to our center between 2007 and 2010 with a diagnosis of head and neck cancer were examined using the medical records. Results. The data from 82 patients were analyzed. There were 72 men (88%) and 10 women (12%). The median age of the patients was 57 (20-80) years. The youngest patients had nasopharyngeal, parahypopharyngeal and paranasal sinus tumors. The most commonly encountered malignancy was the laryngeal cancer, which was found in 37 patients (45%). Fifty-five patients (67%) were Eastern Cooperative Oncology Group 1. The most common grade was the locally advanced stage with 51 patients (62%). At time of the diagnosis, 60 (75%) patients had anemia, 30 (60%) patients had an elevated C-reactive protein, and 72 (89%) patients had weight loss. Squamous cell carcinoma, which was seen in 69 (84%) patients, was the most common histological type. Seventeen (47%) patients had perineural invasion, 17 (47%) patients had lymphovascular invasion, and 12 (32%) patients had extracapsular invasion. Among the patients, the most common grade was grade II, which was found in 34 (42%) patients. The overall median survival was 34 months. The 2-year survival rate was 75% for the patients with early-stage (I-II) cancer and 51% for the patients with locally advanced (III-IVA and B) cancer, the median survival was 10 months in the presence of metastatic disease. The presence of hypertension comorbidity, performance status, location and stage of the cancer, T and N stage, interruption of radiation therapy, C-reactive protein levels, and anemia were the factors that determined survival. Conclusion. The presence of hypertension, performance status, location and stage of the cancer, T and N stage, interruption of radiation therapy, C-reactive protein levels, and anemia were identified as prognostic factors affecting survival in patients with head and neck cancers.

Keywords: Head and neck cancer, radiotherapy, chemotherapy, prognosis

Anahtar Kelimeler

References

  1. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer Statistics, 200 CA Cancer J Clin 2003; 53: 5-26.
  2. Öztop İ. Baş-boyun tümörlerinde hedefe yönelik tedavi. Uluslararası HematolojiOnkoloji Dergisi 2008; 1: 46-56.
  3. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006; 24: 2137Aydıner A, Topuz E. Onkoloji El Kitabı. In: Uslu R, Bilgen C, Esassolak M. Baş ve boyun kanserleri. 1. baskı. İstanbul: Turgut Yayıncılık 2006; pp: 81-115.
  4. Harrison, Louis B, Roy B, Houng, Waun KI. Head and Neck Cancer: A Multidisciplinary Approach. In: Smith BD, Haffty BG. Prognostic Factors in Patients with Head and Neck Cancer. 3rd edition. Philadelphia: Lippincott Williams & Wilkins 2009; pp: 52-70.
  5. Greene FL, Page DL, Fleming ID, Fritz A, Balch CM, Haller DG, Morrow M. AJCC Cancer Staging Handbook. In: TNM classification of malignant tumours. 6th ed. New York:Springer-Verlag; 2002
  6. National Cancer Institute. Cancer Therapy Evaluation Program Common Toxicity Criteria Manuel, Version 2.0 Piccirillo JF, Tierney RM, Costas I, Grove L, Spitznagel EL Jr. Prognostic importance of comorbidity in a hospital-based cancer registry. JAMA 2004; 291: 2441Reid BC, Alberg AJ, Klassen AC, Samet JM, Rozier RG, Garcia I, Winn DM. Comorbidity and survival of elderly head and neck carcinoma patients. Cancer 2001; 92: 2109-16.
  7. Rades D, Fehlauer F, Wroblesky J, Albers D, Schild SE, Schmidt R. Prognostic factors in head-and-neck cancer patients treated with surgery followed by intensity-modulated radiotherapy (IMRT), 3D-conformal radiotherapy, or conventional radiotherapy. Oral Oncol 2007; 43: 535-43.
  8. Abraham J, Allegra CJ, Gulley J. Klinik Onkolji El Kitabı. In: Conley BA, Forastiere AA, Gius D, VanWaes C. Baş Boyun. Çeviri Editörü Alpaslan Mayadağlı, Cem Parlak.1.baskı. İstanbul: Nobel Tıp Kitabevi 2009; s: 3-31.

Details

Primary Language

Turkish

Subjects

-

Journal Section

-

Publication Date

March 22, 2013

Submission Date

September 27, 2012

Acceptance Date

-

Published in Issue

Year 2013 Volume: 35 Number: 1

AMA
1.Atasever Akkaş E, Yücel B, Kılıçkap S, Akgül Babacan N, Altuntaş E. Baş boyun kanserli hastalarda tedavi sonuçları ve prognostik faktörler. CMJ. 2013;35(1):66-75. https://izlik.org/JA45BT54UK